Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

Introduction A major driver of the global autologous cell therapy market is the rising demand for personalized and precision-based medical trea ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Bristol Myers sparked headlines with impressive new data for Breyanzi, its cancer therapy targeting relapsed marginal zone ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety LONDON, UK I June 06, 2025 I Spur ...

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.

SAN DIEGO, CA, USA I June 02, 2025 I Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted ...

Cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other neurological events (NEs) following treatment with lisocabtagene maraleucel (liso-cel; ...